Reappraisal of Atrial Fibrillation: Interaction Between HyperCoagulability, Electrical Remodeling, and Vascular Destabilisation in the Progression of AF- The Tissue Bank Project
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Atrial Fibrillation
- Sponsor
- Academisch Ziekenhuis Maastricht
- Enrollment
- 380
- Locations
- 1
- Primary Endpoint
- Biochemical factors in atrial biopsies and blood samples
- Last Updated
- 7 years ago
Overview
Brief Summary
In the proposed study the investigators aim to clarify the relative contribution of these different mechanisms to the progression of atrial fibrillation (AF). Also the contribution of the individual genetic background will be investigated. Furthermore, the investigators aim to identify clinical parameters and biomarkers informing on the main mechanisms of AF progression in atrial tissue.
For this purpose, in all included patients atrial biopsies will be taken during cardiac surgery.
Detailed Description
An estimated 380 patients will be included Four patient categories will be included enabling to study patients with different stages of AF progression; 1. Patients without history of atrial fibrillation, without new onset atrial fibrillation detected by continuous rhythm monitoring after surgery (control group), 2. Patients without history of atrial fibrillation, with new onset atrial fibrillation detected by continuous rhythm monitoring, 3. Patients with self-terminating atrial fibrillation at inclusion, and 4. Patients with non-self-terminating atrial fibrillation at inclusion. At baseline in-depth phenotyping and genotyping will be performed. Continuous rhythm monitoring will also be performed in all patients. The combination of extensive phenotyping, genotyping and atrial fibrillation burden follow-up offers the unique opportunity to study the atrial tissue alterations and atrial gene expression changes in different stages of atrial fibrillation progression and to correlate these data to the phenotype of the patients.
Investigators
J. G. Maessen
Prof. Dr.
Academisch Ziekenhuis Maastricht
Eligibility Criteria
Inclusion Criteria
- •Age \> 18 years;
- •Undergoing first elective open chest cardiac surgery or surgical ablation for atrial fibrillation;
- •Able and willing to sign informed consent for the registry;
- •Able and willing to undergo implantation of implantable loop recorder (unless the patients has a pacemaker or implantable cardioverter-defibrillator (ICD) with atrial leads)
Exclusion Criteria
- •• Deemed unsuitable or not willing to undergo implantation of implantable loop recorder or attend follow-up visits.
- •Pregnancy.
- •Life expectancy of less than 2.5 years.
- •History of prior cardiac surgery or ablation for atrial fibrillation.
Outcomes
Primary Outcomes
Biochemical factors in atrial biopsies and blood samples
Time Frame: 2.5 year follow up
Biochemical factors in atrial biopsies and blood samples associated with atrial fibrillation and contributing to atrial fibrillation progression
Molecular factors in atrial biopsies and blood samples
Time Frame: 2.5 year follow up
Molecular factors in atrial biopsies and blood samples associated with atrial fibrillation and contributing to atrial fibrillation progression
Genetic factors in atrial biopsies and blood samples
Time Frame: 2.5 year follow up
Genetic factors in atrial biopsies and blood samples associated with atrial fibrillation and contributing to atrial fibrillation progression
Secondary Outcomes
- AF complexity(2.5 year follow up)
- Atrial fibrillation burden(2.5 year follow up)
- Major adverse cardiovascular and cerebrovascular events(2.5 year follow up)
- First recurrent atrial fibrillation;(2.5 year follow up)
- AF progression(2.5 year follow up)
- Number of atrial fibrillation episodes(2.5 year follow up)
- Duration of atrial fibrillation episodes(2.5 year follow up)